YU92003A - Karbapenem jedinjenje - Google Patents

Karbapenem jedinjenje

Info

Publication number
YU92003A
YU92003A YU92003A YUP92003A YU92003A YU 92003 A YU92003 A YU 92003A YU 92003 A YU92003 A YU 92003A YU P92003 A YUP92003 A YU P92003A YU 92003 A YU92003 A YU 92003A
Authority
YU
Yugoslavia
Prior art keywords
carbapenem compound
compound
carbapenem
microbism
remedy
Prior art date
Application number
YU92003A
Other languages
English (en)
Inventor
Hiroshi Matsui
Original Assignee
Kyoto Pharmaceutical Industries Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyoto Pharmaceutical Industries Ltd. filed Critical Kyoto Pharmaceutical Industries Ltd.
Publication of YU92003A publication Critical patent/YU92003A/sh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D477/00—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring
    • C07D477/10—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
    • C07D477/12—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached in position 6
    • C07D477/16—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached in position 6 with hetero atoms or carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 3
    • C07D477/20—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Dobijanje karbapenem jedinjenja predstavljenog formulom (I'): gde je svaki od simbola opisan u specifikaciji i antibakterijskog agensa koji sadrži ovo jedinjenje kao aktivan sastojak. Karbapenem jedinjenje iz ovog pronalaska je superiorno u apsorptivnosti iz gastrointestinalnog trakta nakon oralne primene i veoma je korisno u profilaksi i lečenju infektivnih bolesti (posebno, bakterijskih infektivnih bolesti).[A carbapenem compound represented by the formula (I'): (I') (wherein the symbols have the same meanings as defined in the description); and an antibacterial containing the compound as the active ingredient. The carbapenem compound has excellent absorbability through the digestive tract after oral administration. It is extremely useful in the prevention of and remedy for infectious diseases (especially microbism).
YU92003A 2001-05-21 2002-05-17 Karbapenem jedinjenje YU92003A (sh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2001150874 2001-05-21

Publications (1)

Publication Number Publication Date
YU92003A true YU92003A (sh) 2006-05-25

Family

ID=18995823

Family Applications (1)

Application Number Title Priority Date Filing Date
YU92003A YU92003A (sh) 2001-05-21 2002-05-17 Karbapenem jedinjenje

Country Status (18)

Country Link
US (1) US20040176350A1 (sh)
EP (1) EP1398314A4 (sh)
JP (1) JPWO2002094829A1 (sh)
KR (1) KR20040000466A (sh)
CN (1) CN1511156A (sh)
BG (1) BG108479A (sh)
BR (1) BR0209970A (sh)
CA (1) CA2448670A1 (sh)
CZ (1) CZ296825B6 (sh)
HU (1) HUP0400444A3 (sh)
MX (1) MXPA03010607A (sh)
NO (1) NO20035153L (sh)
NZ (1) NZ530170A (sh)
PL (1) PL366943A1 (sh)
RU (1) RU2289582C2 (sh)
SK (1) SK15822003A3 (sh)
WO (1) WO2002094829A1 (sh)
YU (1) YU92003A (sh)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7232924B2 (en) 2001-06-11 2007-06-19 Xenoport, Inc. Methods for synthesis of acyloxyalkyl derivatives of GABA analogs
US7186855B2 (en) 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US6818787B2 (en) 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
CN100582106C (zh) * 2006-01-27 2010-01-20 上海医药工业研究院 一种吡咯烷硫基碳青霉烯衍生物的制备方法及其中间体
CN101357918B (zh) * 2007-06-22 2011-05-18 山东轩竹医药科技有限公司 含有异硫脲基巯基吡咯烷的培南衍生物
CN101367811B (zh) * 2007-06-28 2010-11-17 山东轩竹医药科技有限公司 碳代青霉烯类抗生素
CN101367806B (zh) * 2007-06-28 2010-11-17 山东轩竹医药科技有限公司 甲酰苯胺取代的巯基吡咯烷碳青霉烯类化合物
ES2477290T3 (es) * 2009-03-13 2014-07-16 Daewoong Pharmaceutical Co., Ltd. Método mejorado para preparar meropenem usando polvo de zinc
EP2968274B1 (en) * 2013-03-15 2019-10-16 Kala Pharmaceuticals, Inc. Meropenem derivatives and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1283906C (en) * 1983-05-09 1991-05-07 Makoto Sunagawa .beta.-LACTAM COMPOUNDS AND PRODUCTION THEREOF
FI81576C (fi) * 1984-12-25 1990-11-12 Sankyo Co Foerfarande foer framstaellning av derivat av 6-(1-hydroxietyl)-2-(1,2-disubstituerade-4-pyrrolidinyltio)-2- karbapenem-3-karboxylsyra, vilka aer anvaendbara som laekemedel.
IE60588B1 (en) * 1986-07-30 1994-07-27 Sumitomo Pharma Carbapenem compound in crystalline form, and its production and use
DE68919508T2 (de) * 1988-04-01 1995-07-20 Sankyo Co 2-(Heterocyclylthio)carbapenemderivate, deren Herstellung und deren Verwendung als Antibiotika.
US5242914A (en) * 1988-04-01 1993-09-07 Sankyo Company, Limited 2-(heterocyclylthio) carbapenem derivatives, their preparation and their use as antibiotics
US5712267A (en) * 1991-06-04 1998-01-27 Sankyo Company,. Limited Carbapenem derivatives, their preparation and their use as antibiotics
JP3048196B2 (ja) * 1991-06-20 2000-06-05 第一製薬株式会社 カルバペネム誘導体
US5360798A (en) * 1991-07-04 1994-11-01 Shionogi Seiyaku Kabushiki Kaisha Aminooxypyrrolidinylthiocarbapenem compounds
EP0882728B1 (en) * 1995-12-21 2002-09-04 Sankyo Company Limited 1-methylcarbapenem derivatives
PL335048A1 (en) * 1997-02-07 2000-03-27 Kyoto Pharmaceutical Ind Carbapenemic compounds, thier usage and intermediate compounds used in their production
SK16382000A3 (sk) * 1998-05-01 2001-05-10 Kyoto Pharmaceutical Industries, Ltd. Karbapénové deriváty, ich vyžitie a ich medziproduktové zlúčeniny
JP2000344774A (ja) * 1999-06-03 2000-12-12 Meiji Seika Kaisha Ltd カルバペネム類の製造法

Also Published As

Publication number Publication date
EP1398314A4 (en) 2004-10-20
US20040176350A1 (en) 2004-09-09
EP1398314A1 (en) 2004-03-17
SK15822003A3 (sk) 2004-06-08
WO2002094829A1 (en) 2002-11-28
RU2289582C2 (ru) 2006-12-20
HUP0400444A2 (hu) 2004-09-28
CA2448670A1 (en) 2002-11-28
KR20040000466A (ko) 2004-01-03
NO20035153D0 (no) 2003-11-20
NO20035153L (no) 2003-11-20
CZ296825B6 (cs) 2006-06-14
NZ530170A (en) 2005-09-30
PL366943A1 (en) 2005-02-07
HUP0400444A3 (en) 2007-02-28
RU2003136767A (ru) 2005-05-10
MXPA03010607A (es) 2004-04-02
CZ20033507A3 (en) 2004-05-12
JPWO2002094829A1 (ja) 2004-09-09
CN1511156A (zh) 2004-07-07
BG108479A (bg) 2005-03-31
BR0209970A (pt) 2004-04-06

Similar Documents

Publication Publication Date Title
UA84266C2 (uk) Дозована лікарська форма у вигляді таблетки або пелети для перорального введення, яка містить інгібітор pde 4 та полівінілпіролідон, способи її одержання та застосування
YU29502A (sh) Proces dobijanja 4"-supstituisanog 9-dezokso-9a-aza-9a derivata homoeritromicina a
AUPR213700A0 (en) Antiviral agents
IL205420A0 (en) Immunoregulatory compounds and derivatives
WO2004026306A3 (en) Pyrazole derivatives as transforming growth factor (tgf) inhibitors
GB9914486D0 (en) Medicaments
GB0031086D0 (en) Medicaments
NO996108L (no) 9-oksinerytromycinderivater
DE602004011966D1 (en) Heterocyclylverbindungen
IL136062A0 (en) Oxazolidinone derivatives and pharmaceutical compositions
GEP20094834B (en) Macrolides, pharmaceutical compositions containing them and their use for treatment of bacterial infections
CA2430967A1 (en) Remedies for bone marrow suppression and infectious diseases and white blood cell count elevating agents
BG108498A (en) New derivatives of oxazolidinones as antibacterial agents
GB0109122D0 (en) Novel compounds
MXPA03010607A (es) Compuesto de carbapenem.
DE60035429D1 (de) Verwendung von sulfodehydroabietinsäure zur behandlung entzündlicher darmerkrankungen
YU66700A (sh) Derivati karbapenema, njihovo korišćenje i intermedijarna jedinjenja istih
CA2386685A1 (en) Use of pleuromutilin derivatives for transdermal treatment of bacterial diseases
AU2002359150A1 (en) Therapeutic heterocycles
CA2417935A1 (en) Anti-inflammatory medicament
AU2001246999A1 (en) New neurokinin antagonists for use as medicaments
WO2003089446A3 (en) 23-o-substituted 5-o-mycaminosyltylonide derivatives
CA2248794A1 (en) Medicament for preventive and treatment for viral infectious diseases
AU2001244999A1 (en) Naphthamide neurokinin antagonists for use as medicaments
WO2003043632A3 (en) Use of bisindolmaleimide and gemcitabine for the treatment of cancer